Literature DB >> 4087367

Increased cardiovascular response to epinephrine in hypertrophic cardiomyopathy.

Y Koga, M Itaya, H Toshima.   

Abstract

To study the role of catecholamines in the pathogenesis of hypertrophic cardiomyopathy (HCM), hemodynamic responses to low and high dose infusions of epinephrine (0.037 and 0.074 micrograms/Kg/min) were compared between 21 patients with nonobstructive HCM and 21 healthy controls, matched for age and sex. During low dose infusion, patients with HCM showed significantly greater responses (p less than 0.05) than controls in echocardiographic left ventricular (LV) end-systolic dimension (-8 +/- 1% vs -4 +/- 1%, mean +/- SEM), fractional shortening (12 +/- 2% vs 7 +/- 1%) and peak systolic velocity of the LV posterior wall (32 +/- 5% vs 15 +/- 4%), but the differences disappeared during high dose infusion. Thus, patients with HCM started to respond to epinephrine earlier than controls and seemed to have an increased sensitivity of beta-adrenergic receptors in the cardiovascular system. As the augmented responses were more evident in younger patients (less than 35 years) who manifested frequent familial occurrences of HCM, the increased sensitivity to catecholamine was postulated to be genetically determined and to be related to the abnormal myocardial hypertrophy of HCM.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4087367     DOI: 10.1536/ihj.26.727

Source DB:  PubMed          Journal:  Jpn Heart J        ISSN: 0021-4868


  2 in total

1.  Short term reduction of left ventricular mass in primary hypertrophic cardiomyopathy by octreotide injections.

Authors:  A I Günal; A Işik; H Celiker; O Eren; H Celebi; S Y Günal; C Lüleci
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

2.  Hypertrophic cardiomyopathy: a desensitized cardiac beta-adrenergic system in the presence of normal plasma catecholamine concentrations.

Authors:  C Schumacher; H Becker; R Conrads; U Schotten; S Pott; M Kellinghaus; M Sigmund; F Schöndube; C Preusse; H D Schulte
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-04       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.